Rapid Response to Penpulimab Combined With Anlotinib and Chemotherapy in a Thoracic SMARCA4‐UT Without PD‐L1 Expression: A Case Report and Review of Literature

Yuanhang Wang, Kelei Zhao, Jingjing Zhang, Xiaohan Yuan, Yanting Liu, Jinghang Zhang, Ping Lu, Min Zhang · 2024

Read Rapid Response to Penpulimab Combined With Anlotinib and Chemotherapy in a Thoracic SMARCA4‐UT Without PD‐L1 Expression: A Case Report and Review of Literature by Yuanhang Wang, Kelei Zhao, Jingjing Zhang, Xiaohan Yuan, Yanting Liu, Jinghang Zhang, Ping Lu, Min Zhang (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11625506.txt.

Description

Yuanhang Wang and co-authors report a fast response in a man with a rare, aggressive chest tumor tied to a missing gene called SMARCA4. Their 2024 case report and literature review describe a fifty-five-year-old whose cancer had spread to lymph nodes, the chest lining, and bones. Tests showed the tumor lacked a marker that often predicts benefit from immune drugs.

A first drug pair failed, and scans showed growth after one cycle. The team switched to a three-way mix of chemotherapy, an immune drug called penpulimab, and a vessel-blocking pill. The tumor then shrank quickly. The authors weigh this rescue path for a cancer that still has no standard effective treatment.

Catalog record

CREATORYuanhang Wang, Kelei Zhao, Jingjing Zhang, Xiaohan Yuan, Yanting Liu, Jinghang Zhang, Ping Lu, Min Zhang
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE16 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11625506

Browse the full library · About the Tower of Babel